

Table 14.8
De Novo Posttransplant Solid Malignancy, 1998 to 2007
Liver Recipients

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Total # of Post-Tx Malignancies	336	336	267	261	278	214	241	213	130	44
Malignancies by Type										
Squamous/Basal Cell Carcinoma	136	128	122	103	111	76	80	76	30	13
Melanoma	6	15	4	6	9	8	5	11	6	2
Kaposi Sarcoma	-	5	2	1	3	-	1	-	-	-
Central Nervous System	5	1	1	3	2	1	3	-	3	1
Genito-Urinary (1)	44	28	28	30	17	24	19	16	11	4
Gastro-Intestinal (2)	47	45	24	32	20	24	27	22	16	6
Primary Hepatic Tumor	14	14	14	7	16	12	17	22	9	2
Metastatic Hepatic Tumor	14	6	8	12	14	11	17	14	15	2
Larynx/Bronchi/Lung	45	47	34	35	44	24	42	27	25	7
Breast/Thyroid	5	16	6	12	12	9	8	6	5	1
Leukemia	3	-	-	1	2	3	3	2	-	1
Sarcoma (3)	-	1	1	-	3	3	2	1	-	-
Other	14	21	20	13	22	15	14	15	7	5
Unknown	3	9	3	6	3	4	3	1	3	-
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	40.5%	38.1%	45.7%	39.5%	39.9%	35.5%	33.2%	35.7%	23.1%	29.5%
Melanoma	1.8%	4.5%	1.5%	2.3%	3.2%	3.7%	2.1%	5.2%	4.6%	4.5%
Kaposi Sarcoma	-	1.5%	0.7%	0.4%	1.1%	-	0.4%	-	-	-
Central Nervous System	1.5%	0.3%	0.4%	1.1%	0.7%	0.5%	1.2%	-	2.3%	2.3%
Genito-Urinary (1)	13.1%	8.3%	10.5%	11.5%	6.1%	11.2%	7.9%	7.5%	8.5%	9.1%
Gastro-Intestinal (2)	14.0%	13.4%	9.0%	12.3%	7.2%	11.2%	11.2%	10.3%	12.3%	13.6%
Primary Hepatic Tumor	4.2%	4.2%	5.2%	2.7%	5.8%	5.6%	7.1%	10.3%	6.9%	4.5%
Metastatic Hepatic Tumor	4.2%	1.8%	3.0%	4.6%	5.0%	5.1%	7.1%	6.6%	11.5%	4.5%
Larynx/Bronchi/Lung	13.4%	14.0%	12.7%	13.4%	15.8%	11.2%	17.4%	12.7%	19.2%	15.9%
Breast/Thyroid	1.5%	4.8%	2.2%	4.6%	4.3%	4.2%	3.3%	2.8%	3.8%	2.3%
Leukemia	0.9%	-	-	0.4%	0.7%	1.4%	1.2%	0.9%	-	2.3%
Sarcoma (3)	-	0.3%	0.4%	-	1.1%	1.4%	0.8%	0.5%	-	-
Other	4.2%	6.3%	7.5%	5.0%	7.9%	7.0%	5.8%	7.0%	5.4%	11.4%
Unknown	0.9%	2.7%	1.1%	2.3%	1.1%	1.9%	1.2%	0.5%	2.3%	-
Total # of Patients	237	244	213	204	226	171	187	167	99	34

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.